Dysregulation of immune cell and cytokine signalling correlates with clinical outcomes in myelodysplastic syndrome (MDS)-Reference-Cited by-同舟云学术

Dysregulation of immune cell and cytokine signalling correlates with clinical outcomes in myelodysplastic syndrome (MDS)

Published:2022-02-03 Issue: Volume: Page:
ISSN:0902-4441
Container-title:European Journal of Haematology
language:en
Short-container-title:European J of Haematology

Author:

Chee Lynette¹²³⁴^ORCID,Ritchie David¹²³⁴,Ludford‐Menting Mandy¹,Ripley Jane¹⁵,Chung Jessica⁶,Park Daniel⁶,Norton Sam⁷,Kenealy Melita⁴⁸⁹,Koldej Rachel¹³

Affiliation:

1. Australian Cancer Research Foundation (ACRF) Translational Laboratory The Royal Melbourne Hospital Melbourne Victoria Australia

2. Department of Clinical Haematology The Royal Melbourne Hospital and Peter MacCallum Cancer Centre Parkville Victoria Australia

3. Department of Medicine The University of Melbourne Parkville Victoria Australia

4. The Australasian Leukaemia and Lymphoma Group Richmond Victoria Australia

5. Liverpool Hospital Liverpool New South Wales Australia

6. Melbourne Bioinformatics The University of Melbourne Parkville Victoria Australia

7. Nanix Limited Dunedin New Zealand

8. Cabrini Hospital Malvern Victoria Australia

9. Monash University Clayton Victoria Australia

Funder

Victorian Cancer Agency

Publisher

Wiley

Subject

Hematology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/ejh.13742

Reference36 articles.

1. International scoring system for evaluating prognosis in myelodysplastic syndromes;Greenberg P;Blood,1997

2. Revised international prognostic scoring system for myelodysplastic syndromes;Greenberg PL;Blood,2012

3. Further analysis of trials with azacitidine in patients with myelodysplastic syndrome: studies 8421, 8921, and 9221 by the Cancer and Leukemia Group B;Silverman LR;J Clin Oncol,2006

4. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher‐risk myelodysplastic syndromes: a randomised, open‐label, phase III study;Fenaux P;Lancet Oncol,2009

5. Minimizing risk of hypomethylating agent failure in patients with higher‐risk MDS and practical management recommendations;Santini V;Leuk Res,2014

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Single-cell Multiomics Analysis of Myelodysplastic Syndromes and Clinical Response to Hypomethylating Therapy;Cancer Research Communications;2024-02-12

2. Analyzing Differences in Hematological and Immunological Characteristics Related to Common Gene Mutations in Myelodysplastic Syndromes;Discovery Medicine;2024

3. MicroRNA profiling in aplastic anemia reveals similarities between secondary myelodysplastic syndromes arising from clonal progression and de novo MDS;Frontiers in Hematology;2023-09-15

4. Immunophenotypic changes of monocytes in myelodysplastic syndrome and clinical significance;Clinical and Experimental Medicine;2022-08-02